The CCAAT/enhancer-binding protein-alpha (CEBPA) is a transcription factor strongly implicated in myelopoiesis through control of proliferation and differentiation of myeloid progenitors. Recently, several works have reported the presence of CEBPA-acquired mutations in hematological malignancies. In this work, we analyzed characteristics of mutations and their correlation with disease characteristics described in previous studies. In the 1175 patients reported, 146 CEBPA mutations were identified in 96 patients. Mutations were found in the whole gene sequence, but cluster regions were clearly identified. Furthermore, two categories of mutations were reported: out-of-frame ins/del often in the N-terminal region, and in-frame ins/del often in the C-terminal region. CEBPA mutations were reported exclusively in acute myeloid leukemia (AML) (according to WHO classification criteria) and mutated patients preferentially belonged to M1, M2 and M4 FAB subtypes. All but one case belonged to the 'intermediate' prognostic subgroup of MRC classification. In the absence of poor prognostic factors, patients with CEBPA mutation had favorable outcome, very similar to that of the t(8;21), inv(16), t(15;17) subgroup. Systematic analysis of CEBPA mutations, in addition to that of alterations in master genes of hematopoiesis, may be useful to assess the prognosis of AML particularly in patients belonging to the 'intermediate' prognostic subgroup.
Introduction
Among the many oncogenes affecting proliferation and cell death, anomalies of the genes implicated in the closely regulated pathways of hematopoietic differentiation are key oncogenic events. 1 In acute myeloid leukemia (AML), cell differentiation arrest can occur at different levels by alteration of specific genes like those of the CBF complex. 2 The CEBPA gene (located on chromosome 19q13.1 band) belongs to the CCAAT/enhancer-binding protein family, which is involved in the balance between cell proliferation and terminal differentiation. CEBPA gene mRNA can be translated from the first AUG encoding the 42-kDa normal isoform and also from the second AUG (nt 508-510) encoding the 30-kDa normal isoform, which has lost the 119 first AA including the TAD1 functional domain. The functions of CEBPA 30-kDa protein are not well known. Nevertheless, Pabst et al 3 demonstrated that this shorter CEBPA protein had lost normal CEBPA functions and had dominant negative effect on 42-kDa wild-type (wt) CEBPA. The 42-kDa CEBPA protein has four principal domains: the C-terminal part containing a leucine zipper domain mediating homo-or heterodimerization; the DNA-binding domain (DBD), a basic positively charged domain able to interact with specific DNA sequences; and two regulatory and transactivating domains TAD1 and TAD2 ( Figure 1) .
The 42-kDa normal protein acts as a transcription factor with a crucial role during differentiation of various cell types including hepatocytes, adipocytes, enterocytes, keratinocytes, lung, mammary gland cells and hematopoietic cells. In hematopoiesis, CEBPA plays a pivotal role in early stages of myeloid differentiation and is particularly expressed in myelomonocytic cells. [4] [5] [6] [7] [8] CEBPA has multiple actions such as downregulation of C-MYC expression allowing differentiation, direct upregulation of the expression of granulocytic lineage-specific genes and synergistic action with other key genes in myeloid development including CBF complex genes and PU.1.
5,9-11 In addition to specific DNA binding, CEBPA could act by proteinprotein interaction. The principal partners of those interactions are p21, CDK2, CDK4 and E2F. Repression of E2F-dependent transcription genes by CEBPA had previously been shown to be a critical event in suppressing cellular proliferation and inducing granulocytic or adipocyte differentiation. CEBPA also inhibits cell proliferation by activating transcription of p21/WAF1, by stabilizing p21 and inhibiting CDK2 and CDK4. [12] [13] [14] CEBPA expression begins with the commitment of myeloid lineage precursors and is upregulated during granulocytic differentiation. 7 CEBPA-defective mice have no mature granulocytes, whereas cells of the other lineages are not affected. 15 In addition, CEBPA expression could block monocytic differentiation. 16 The strong implication of CEBPA in granulocytic differentiation points to this gene as a key target in leukemogenesis, as shown now in many studies. Pabst et al 3 found that events leading to the loss of CEBPA function observed in AML contribute to leukemogenesis by blocking granulocytic differentiation. Moreover, myeloid blasts observed in those cases were committed myeloid cells generally classified in the M1 or M2 FAB AML subtypes. 17 Recently, three mechanisms of CEBPA inactivation have been reported. One is downregulation of CEBPA expression by the AML1-ETO fusion transcript in t (8, 21) leukemia cells. In this model, conditional expression of CEBPA in those cells is sufficient to trigger granulocytic differentiation. 18 The second mechanism is inhibition of the translation of CEBPA mRNA by interaction with hnRNPE2, induced by BCR-ABL fusion protein. 19 This mechanism could contribute to the transition from chronic phase to myeloid blast crisis in CML, by blocking myeloid differentiation. Finally, inactivating CEBPA mutations have been reported in hematological malignancies, especially in AML. 3, [20] [21] [22] [23] [24] [25] [26] In this review, we focused on CEBPA mutations and how, through inactivation of transcriptional properties of the CEBPA protein, they could lead to leukemogenesis.
Overview of CEBPA gene mutations reported
In the last 3 years, 1175 patients were screened for CEBPA mutations in seven studies. 
Cytogenetic findings
Cytogenetic data was available in 83 of the 87 mutated patients (see online additional data). Only one had a complex karyotype with more than three abnormalities; 58 cases (70%) had a normal karyotype and eight (10%) had only one abnormality. Other clinical and biological correlations (Table 2) When they were studied, no correlation was observed between CEBPA mutations and age, sex, WBC count and bone marrow blast percentage.
Prognostic value of CEBPA mutations
Four studies have evaluated the prognostic impact of CEBPA mutations in 71 mutated patients, by comparison to 670 patients without CEBPA mutation. 21, 22, 24, 27 In these four studies, the complete remission rate was not significantly different in patients with or without CEBPA mutations, but all studies except that of Snaddon et al 21 showed better relapse-free survival (RFS) or overall survival (OS) in mutated cases. Discrepancies between Snaddon et al 21 and other studies could have been due to some characteristics of their mutated cases, including higher peripheral blood blast count (median of 93 10 9 /l vs o24 10 9 /l in the mutated cases of other studies), the localization of mutations (five of eight mutated patients had a single alteration of the C-terminal part of CEBPA protein vs zero of 27 in the other studies), and, although this is more speculative, the fact that five of their eight mutated patients received standard dose AraC instead of highdose AraC in the other studies.
An analysis of cooperating mutations, made in two studies, showed no difference in the incidence of FLT3 and MLL alterations in CEBPA-mutated and -nonmutated patients. 24, 27 However, in patients with CEBPA mutation, Preudhomme et al, 24 showed that the presence of FLT3 internal tandem duplication (FLT3-ITD) had a negative prognostic influence, whereas, in the study of Frö hling et al, 27 the presence of FLT3-ITD or FLT3 mutations had no prognostic impact. Nevertheless, in the two studies, the size of the population studied was too small for definite conclusions (15 patients in Preudhomme et al, study 24 and 36 patients in Frö hling et al, study 27 ).
CEBPA mutation profile in mutated cases (Table 3) A total of 45 patients had a single CEBPA alteration, whereas 42 cases had multiple alterations resulting from biallelic mutations or from several mutations on the same allele. There was no (Figure 1 ).
Characteristics of CEBPA mutations
Until now, 146 CEBPA mutations have been described in 96 patients, 3, [21] [22] [23] [24] [25] 27 including nine isolated silent mutations without transcriptional effect in nine patients and 137 nonsilent CEBPA mutations in 87 patients (five missense mutations, 54 inframe ins/del mutations, 78 nonsense mutations including five STOP codon point mutations and 73 out-of-frame ins/del mutations inducing a STOP codon downstream). Reported mutations were nonrandomly distributed all over the CEBPA gene sequence and occurred in five regions of the protein (regions R1 to R5) (Figure 1 ): R1 corresponding to the AA before the Poly-Gly domain, R2 between the Poly-Pro and the Poly-Gly domain, R3 corresponding to the N-terminal part of the DBD and the region just before the DBD domain, R4 corresponding to the C-terminal part of the DBD and to the N-terminal part of the b-Zip domain (fork region), R5 corresponding to the C-terminal part of the B-zip domain.
R1 and R4 were the two main cluster regions as 76% of the 137 nonsilent mutations belonged to these regions. Moreover, the distribution of the type of mutations between these two regions was heterogeneous. Nearly all out-of-frame ins/del nonsense mutations occurred in R1 region, whereas most 54 inframe ins/del mutations occurred in R4 region. Functional study of the mutated protein showed important loss of transactivation properties of CEBPA in almost all cases of mutation A minor cluster region (R2 region) has been reported by Frö hling et al, 27 who found 14 recurring mutations in the TAD2 domain. Those alterations were 6 bp duplications or 3 bp deletions inducing the addition of H-P AA in a motif of three H-P repeats, or deletion of one P in a motif of seven P repeats. Of the nine cases with TAD2 mutation, seven had no 30-kDa dominant negative form. The significance of such recurrent alterations (ie repeats of GCC nucleotide triplets) remains to be understood.
Overall, in 55 of the 87 mutated cases, mutations lead to the synthesis of the dominant negative 30-kDa form, which inhibits CEBPA normal function. No significant correlation between localization, number of mutations and FAB subtypes could be established (Figure 1 ). Of note, however, is the fact thatin case of multiple mutations, patients had preferentially M1-AML (45%), whereas, in case of single mutation, patients had preferentially M2-AML (44%) ( Table 3) .
Pathogenetic role of CEBPA mutations
How CEBPA mutations can contribute to leukemogenesis in AML and to prognosis remains uncertain. It has been shown that CEBPA mutations induced modifications in the gene expression profile obtained from blast cells, and that, if AML patients were classified according to the gene expression profile, CEBPA mutated patients segregated in two homogeneous clusters. 29 A review of the currently published CEBPA mutations suggests two main types of mutated cases. The first group contains patients with at least one mutation in R1 or R2 clustering regions leading to increased translation of the 30-kDa isoform from the second AUG downstream of the mutation, inducing the indirect loss of CEBPA main function in a dominant negative manner. The other group contains patients where CEBPA gene mutations result in loss of the main transregulatory function of CEBPA, mainly due to multiple alterations of the gene; absence of wt CEBPA protein in blast cells could explain the differentiation arrest of these cells.
How can mutations contributing to the loss of function of a master gene in early myeloid differentiation result in a myeloid type of leukemia? It has previously been reported that biallelic mutations of another early myeloid differentiation gene (AML1/ RUNX1) could induce M0 AML subtype. 2 Furthermore, mice models of CML blast crisis with CEBPA knockout result in immature erythroid leukemia 30, 31 and expression of a dominant negative 30-kDa CEBPA protein inhibits differentiation of myeloid and erythroid progenitors. 32 On the other hand, all CEBPAmutated patients reviewed in this work had M1, M2, M4 or M5 AML subtypes, clearly showing persistence of myeloid differentiation in blast cells. However, in mutated cases with multiple alterations of CEBPA, preventing expression of wt protein, or in single alterations with expression of p30 dominant negative form, the persistence of CEBPA residual cellular functions has been demonstrated. 31, 33, 34 Therefore, those cases are not identical to KO models since the loss of transactivating properties is dependent of on cis-regulating elements of the CEBPA target genes. Moreover, other members of the CEBPA family, including CEBPB and CEBPE, could partially prevent the effects of the loss of function of mutated CEBPA and allow incomplete myeloid differentiation resulting in M1, M2, M4 and M5 blasts.
Pabst et al 18 demonstrated that, when CEBPA nonsense mutations occurred before the second AUG, the 30-kDa CEBPA isoform was increased by 4.2-8.6-fold compared with unmutated cases. This shorter form of CEBPA lacks antiproliferative activity 35 and most of the transactivation properties of the normal protein, 36, 37 and acts dominantly on wt CEBPA by inhibiting DNA binding of CEBPA on targeted genes. 3 Indeed, in the presence of equal amounts of 42-kDa and 30-kDa in vitro, the 30-kDa isoform totally abolished transactivation of a plasmid reporter by the full-length CEBPA protein. 18 The 30-kDa protein binds DNA with only 14% affinity compared with the full-length protein and can inhibit DNA binding of wt CEBPA. 3 However, the 30-kDa isoform does not inhibit 42-kDa normal function on each CEBPA-transregulated genes. For example, MPO gene expression is not abrogated by the 30-kDa form. 31, 34 The predominance of M1 and M2 FAB subtypes in CEBPA-mutated AML, with partial myeloid differentiation block in blast cells, is compatible with this effect and the higher incidence of CEBPA mutations in M1, M2 and M4 FAB subtypes supports a critical role of CEBPA gene function in showed that PML-RARa blocked CEBPA activity. Those similarities could contribute to explain why AML with CEBPA mutations have favorable prognosis in AML. This favorable prognostic value and the predominance of CEBPA mutations in M1, M2 and M4 AML justifies, in our opinion, systematic screening for CEBPA mutations in those AML groups, especially in patients belonging to the intermediate prognosis cytogenetic group. Analysis of the currently reported CEBPA mutations has shown a nonrandom distribution of mutations in the coding sequence of the gene, with two principal mutation cluster regions (R1 and R4). Mutation types are not equally distributed between the two regions as more than 87% of in-frame ins/del mutations occurred in the R4 region (if we exclude the TAD2 inframe ins/del) and nonsense out-of-frame mutation localized in the R1 region in 82% of the cases. As the size of ins/del mutations is shorter in out-of-frame ins/del mutations, the best screening methods may differ for each region: gene scan method after amplification may be preferable for the C-terminal region (R3 and R4 regions) and direct sequencing for the N-terminal region (genomic sequence coding for AA 1-200, including R1 and R2 region). By these methods, 92% of the 137 CEBPA mutations and 100% of the mutations inducing the synthesis of dominant negative 30-kDa isoform would have been identified.
Systematic screening of CEBPA mutations in association with the search of other alterations in master genes implicated in leukemogenesis such as FLT3, MLL or RAS should probably be performed systematically in AML, particularly in patients belonging to the 'intermediate' prognostic group, to determine more precisely the impact of the association between genetic events on overall survival and therapeutic response in large cohorts of patients.
